Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 16/20 | 0.45 |
| ▸ | HTR2B | P41595 | 12/20 | 0.45 |
| ▸ | HTR2A | P28223 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21003025 | 0.98 | POLB (0.47) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL1528578 | 0.84 | HTR2C (0.34) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL16060483 | 0.83 | HTR2C (0.33) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL31598020 | 0.79 | HTR2C (0.45) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL12878847 | 0.74 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL4135011 | 0.74 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL2449506 | 0.74 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL2183634 | 0.74 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL30790976 | 0.74 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR2A | |
| SCHEMBL25574537 | 0.74 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2991989-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | Pfizer Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | POLB 2008/4885SMN1; SMN2 4124/4885HTR2C 871/4885 |
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | POLB 3448/4885SMN1; SMN2 803/4885HTR2C 3902/4885 |
| US-20150353579-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | POLB 2008/4885SMN1; SMN2 4124/4885HTR2C 871/4885 |
| US-20220153721-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | POLB 3448/4885SMN1; SMN2 803/4885HTR2C 3902/4885 |
| US-20150080401-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | POLB 2008/4885SMN1; SMN2 4124/4885HTR2C 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.